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SUMMARY 
Cyclophospbamide significantly diminished the canine humoral antibody response 
to sheep red blood cells and tended to prevent arterial lesions in renal homografts. 
However, cyclophosphamide failed to prolong renal homograft survival when 
administered to dogs as the sole immunosuppressive agent, and it did not add to the 
effectiveness of azathioprine when given as a supplement to the azathioprine and 
administered simultaneously or sequentially. 
INTRODUCTION 
Although cyclophosphamide (CytoxanR) has been known for a number of years to be a 
superior immunosuppressive agent for the mouse (Berenbaum & Brown, 1964: Fox, 1964; 
Frisch & Davies, 1965), rat (Santos & Owens, 1962), guinea·pig (Caine & Leibowitz, 1963), 
rabbit (Brody, Jones & Haines, 1965; Jones et al., 1963) and man (Santos et al., 1970), it 
did not receive an extensive trial in a clinical transplantation program until relatively 
recently (Starzl et 01., 1971). The reluctance to treat human organ recipients with cyclo-
phosphamide was at least partially attributable to its failure, as reponed by Reams (1963) 
and Zukoski, Callaway & Rhea (1963), to prolong the survival of canine renal homografts, 
when used as the sole immunosuppressive agent. 
The results in dogs with combination therapy have been less clear. In 1962, Caine, 
Alexandre & Murray had reported that the combination of cyclophosphamide and azathio-
prine, as opposed to azathioprine only, actually decreased the mean sun'ival times of canine 
renal recipients as the result of increased bone marrow toxicity. However, MacPhee & 
Wright (1964) concluded that cyclophosphamide plus Actillomycin D prolonged the survi-
val of canine lung homografts in comparison with untreated animals. Preston et al. (1966) 
came to much the same conclusion after treating recipients of intestinal homografts with 
cyclophosphamide and corticosteroids. Caves, Dong & Shumway (1973) in analysing their 
series of canine cardiac homotransplantations, found a significantly greater mean survival 
Correspondence: Dr Charles W. Putnam, Department of Surgery. Univef"!l:- of Colorado Medical 
Center, 4200 East Ninth Avenue, Denver, Colorado 80220, U.S.A. 
I 323 
• 
'" ~: 
'" i 
>-
'. 
't 
';. 
' . 
. , 
.. 
1 
" 
-; 
'1 
J, 
J 
.... -
",1/;' 
" K~
·f· 
, 
.: 
!. 
;-K~ 
. 
'f 
.-'. 
:';' 
K~~ 
.. 
k 
;1; 
· . 
! .. !irlR~";rK~~~~*¥~III;;fi l~D:-";··Dp~ ... 2' !I"IK"I;~: DiflAtoKraii:KyDiDliifrDr?ADi4¥~~:ii#jifC~"DDDi E;D~iey+;I;gi 
~ 
324 c. W. Putnam et ai. 
time when the recipients received cyclophosphamide in addition to horse antidog thymocyte 
globulin, than when they were treated with globulin only. However, using the same test 
systems, Kondo et al. (1974) were unable to demonstrate prolonged survival with the 
combination of cyclophosphamide and prednisone. 
The purpose of the present study was to re-examine the potency of cyclophosphamide as 
an immunosuppressant in the dog by determining its ability, first, to inhibit the antibody 
response to sheep red blood cells, and second, to prolong renal homograft survival. In the 
latter trials, cyclophosphamide was administered both alone and with azathioprine. 
MATERIALS AND METHODS 
On day 0, 1 rnJ/kg body weight of washed sheep red cells (SRBC) resuspended in saline to 20% by volume was 
given intravenously to adult mongrel dogs. On the day before, and thereafter at about 2·day intervals, serum 
samples were obtained for the determination of anti-sheep erythrocyte antibody titres by a standard micro-
plate method. 
Group 1 (six dogs). Cyclophosphamide, 2 mg/kg body weight per day orally, was started 2 days before the 
primary immunizing dose of SRBC and continued for 13 days afterward. 
Group 2 (six dogs). Two weeks after the first injection of SRBC a second dose was given intravenously. 
Cyclophosphamide was begun 2 days before the booster immunization. The cyclophosphamide dose was 
again 2 mg/kg orally, given daily for 2 weeks. 
Group 3 (six dogs). Each dog received a primary and a secondary injection of SRBC spaced 2 weeks apart. 
No cyclophosphamide was given. These animals served as controls for groups 1 and 2. 
Group 4 (eight dogs). Each dog received a primary injection of SRBC on the 3rd day after starting cyclo-
phosphamide, 3 mg/kg/day orally. 
Group S (nine dogs). Each dog received a primary injection of SRBC, but no cyclophosphamide. These 
animals served as controls for group 4. 
TABLE I. Mean survival times and incidence of leukopaenia in 128 canine recipients of renal homografts 
Group 
A 
B 
C 
D 
E 
F 
G 
H 
Controls 
Treatment (mgJkg/day) 
Days Q.-4 
No. of Cyclo· Azat 
dogs (mg) (mg) 
11 3 
IS 1 
11 2 
Day S onward 
Cyclo· 
(mg) 
3 
2 
2 
Azat 
(mg) 
1 
10 2 1 2 
11 3 3 
20 3 2 
9 3 
10 2 
10 3 2 
21 
• Cyclo = cyclophosphamide (CytoxanR). 
t Aza = azathioprine OmuranR), 
Mean survivalt 
±s.d. (days) 
12,S±S'2 
15'5± 10·6 
17·0±7·7 
2H± 10'3 
25·8± 13·0 
I9'7±10'4 
15'6± 13·1 
17·6± 13·2 
26'9± 11·7 
12'7±9'1 
P value§ 
NS 
NS 
NS 
P< 0·005 
P< 0·01 
P< 0·05 
NS 
NS 
P< 0·005 
Leukopaenia ** 
No. of 
dogs 
3 
3 
7 
5 
4 
3 
0 
1 
0 
0 
Percentage 
27 
20 
64 
50 
36 
15 
0 
10 
0 
0 
::: In computing (he mean survivals, no dog was given credit for living more than 50 days. 
§ Each group is compared to the control series . 
•• White blood cell count < 3000/mmJ on two consecutive determinations. 
Cyclophosphamide immunosuppressioll ill the dog 
Renal hOlllogrofts. Renal transplantation to the right iliac fossa with contemporaneous bilateral nephrec-
tomy was performed in 159 dogs. r n most instances, kidneys were exchanged bctw~n two recipients of 
different treatment g'oups. Alternatively, a common donor supplied kidneys to tv-o recipients enlisted in 
different drug programmes. White blood cell counts and blood urea nitrogen le\ cis were measured three 
times a week. 
The treatment protocols for each of the ten groups are given in Table 1. Treatment was begun either on the 
day of operation (Groups A-G and I) or on the 5th post-operative day (Group HI and was continued until 
death in all groups but G, in which therapy was confined to a 5-day period. 
Thirty-one animals dying within 5 days of transplantation were excluded from the study. For the purposes 
of statistical analysis, no dog was given credit for surviving more than 50 days; animals living beyond the 
arbitrary limit were killed. 
At autopsy a sample of the homograft was taken, fixed in formalin and processed for light microscopy. 
Tissues from ninety-two of the 128 5-day survivals were available for histopathological analysis. The presence 
or absence of various features which are often associated with rejection were noted (Table 2). 
TABLE 2. Analysis of histological lesions in ninety-two canine renal homografts tre2ted \l.;th various 
combinations of cyclophosphamide and azathioprine 
Kidneys showing various histological changes 
in each treatment group· e~F 
Type of lesion Control A C D E F G H I 
Mononuclear cell infiltration 
of interstitium 100 71 40 40 42 80 86 90 40 
Oedema of interstitium 100 57 30 29 67 67 100 90 40 
Fibrinoid necrosis of walls of 
arterioles 86 14 14 14 18 50 i5 50 10 
Fibrinoid necrosis of walls of 
interlobular arteries 86 14 14 14 9 44- 63 40 10 
"' See Table 1 for treatment schedules. Group B was not studied histologically. 
Statistical anolysis. In groups 1-3, haemagglutinin titres were measured on the same days in all dogs, so 
that a one-way analysis of variants with Student's t-test could be carried out. In addition.. the groMh curve 
technique of Grizzle & Allen (1969), in which comparisons are made after reducing: [he curves to poly-
nomials, was used to compare the overall response curves for groups 1 and 2 to that of rontrol group 3. 
Since the haemagglutinin titres of animals in groups 4 and 5 were not always measured on the same days, 
the statistical methods described above rould not be applied. Instead, polynomial regression curves were 
fitted to the haemagglutinin response curves of each dog and the resulting mean curves compared by the 
randomization test of O. Zerbe and S. Walker (unpublished data). 
Statistical comparison of mean survivals of the homograft recipients in groups A to I and the control dogs 
were made with Student's t-test. 
RESULTS 
SRBC antibody response 
The haemagglutinin response curves for the five groups of dogs are shown graphically in 
Figs 1 and 2. Those animals receiving 2 mg/kg of cyclophosphamide for 1 days before and for 
13 days after the primary immunizing dose of red cells (group I) appeared to show a parti-
ally suppressed antibody response when compared to the controls (group 3), but these 
differences were statisticaIly significant (P < 0·05) only on days 5- I I (Fig. I). When the over-
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FIG. 1. Mean haemagglutinin titres for three groups of six dogs each after Lv. injections of 
SRBC (arrows). Cyclophosphamide (2 mg/kg orally) was given daily to dogs in groups 1 and 
2 forthe intervals indicated by the cross·hatched bars. (-) Group I; (- - -) group 2; (- . - .) 
group 3. 
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FIG. 2. ~fean haemagglutinin titres after i.v. injections of SRBC (arrow). Group 4 (eight dogs) 
received cyclophosphamide (3 mg/kg orally) daily. The nine dogs of group 5 received no cycl~ 
phosphamide. (-) Group 4; (---) group 5. 
all response curves of groups 1 and 3 were compared, they were not significantly different. 
Similarly, the anamnestic response to a second injection of SRBC (Fig. 1) seemed to be less 
forceful in the cyclophosphamide-treated dogs (group 2) than in the control animals (group 
3). Although a day-by-day comparison revealed a significant difference only on day 31, the 
overall response curve of group 2 was significantly (P<O'OI) depressed in comparison to 
group 3. Dogs in group 4, which received 3 mg/kg/day of cyclophosphamide, similarly 
showed a diminution in the antibody response to SRBC cells (Fig. 2). This difference was 
significant at the P < 0·0 1 level when compared to the response curve of the control animals of 
group 5. 
Renal homografTs 
Thirty-one recipients died within 5 days of operation and were eliminated from the study; 
the loss rate \ .... as approximately the same in each experimental group. The mean survival 
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times of the remaining 128 recipients are given for the nine treatment groups plus the 
controls in Table 1. 
When cyclophosphamide was administered as the sole immunosuppressive agent in doses 
of 2 or 3 mg/kg (groups A, B and G), the post-operative sun-ivaI was not significantly 
different from that of the controls. 
In groups C and D, cyclophosphamide and azathioprine \vere gi\en concomitantly, the 
total dosage being 3 mg/kg/day. The survival was significantly (P<0-005) prolonged when 
the azathioprine component of therapy was 2 mg/kg, but not when the azathioprine dose 
was {)nly 1 mg/kg. 
Dogs in group F received cyclophosphamide for 5 days, then were switcbed to azathio-
prine. The mean survival time was prolonged (19-7 days, P<0-05), but it was not signifi-
cantly different from that of group H, which received only the azathioprine component of the 
treatment programme (17-6 days), and it was distinctly inferior to that of the recipients of 
groups E and I which were treated with azathioprine from the outset (25'8 and 26·9 days, 
respectively). 
Leukopaenia Cfable 1) was most frequent in animals receiving combination therapy 
(groups C and D) and in animals treated with 3 mg/kg of azathioprine continuously (group 
E). Nevertheless, a significant proportion of dogs receiving cyclophosphamide only for more 
than 5 days (groups A and B) were severely leukopaenic at the time of death. 
Histopathological examination of the renal homografts (Table 2) showed that cyclophos-
phamide when administered as the sole immunosuppressive agent was ineffective if given at a 
dose of 3 mg/kg/day on days 0-4 only (group G). However, if treatment was continued for 
longer (group A) the incidence of fibrinoid necrosis of the walls of arterioles and small 
arteries in the grafts was' greatly reduced although cellular infiltration was only slightly less. 
When cyclophosphamide and azathioprine were given concomitantly (groups C and D) 
the frequency of both vascular lesions and cellular infiltration in the graft was greatly 
reduced. The combined effect of 2 mg/kg/day cyclophosphamide and 1 mg/kg/dayazathio-
prine (group C) was as successful in preventing these lesions as a higher dose of azathioprine 
alone (groups E and 1)_ 
DISCUSSION 
The present investigation confirms that cyclophosphamide is not protective of transplanted 
kidneys in the dog. In the thirty-five recipients of renal grafts treated with cyclophosphamide 
only, there was no prolongation of survival. In an additional forty-one dogs in which cyclo-
phosphamide and azathioprine were combined in three different treatment schedules, the 
survival times appeared to mirror only the azathioprine component of therapy, with no 
demonstrable additive effect attributable to cyclophosphamide. However, histopathological 
analysis showed that although cyclophosphamide alone dia not appreciably reduce the 
infiltration of the graft by mononuclear cells, a dose of 3 mg/kg/day did greatly decrease the 
incidence of fibrinoid necrosis of the walls of the arterioles and interlobular arteries. The 
selective inhibition of vascular lesions in the grafted kidneys is interesting, in view of the 
baemagglutinin antibody response data, because evidence is accumulating that these arterio-
lar and arterial changes are induced by humoral antibody (Jeannet et al., 1970; O'Connell & 
Mowbray, 1973). 
The failure to impair the cell-mediated component of the homograft reaction does not 
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fully explain the inability of cyclophosphamide to prolong graft survival in dogs. In the 
guinea-pig and mouse cyclophosphamide has been shown to suppress the function of B 
lymphocytes preferentially as compared with T lymphocytes (Poulter &' Turk, 1972; Turk 
& Poulter, 1971). The same has been assumed to apply to humans. Yet in all three species, 
cyclophosphamide provides substantial protection to skin or renal homografts (Berenbaum 
& Brown, 1964; CaIne & Leibowitz, 1963; Fox, 1964; Frisch & Davies, 1965; Maguire & 
Maibach, 1961; Starzl et a/., 1971). 
One possible explanation for the inability of cyclophosphamide to protect homo grafts in 
the dog could be that the drug does not undergo efficient conversion in the canine liver, an 
obligatory step for its pharmacological activation. However, the enzymes required, the· 
mixed function oxidase system of hepatic microsomes, are well represented in the dog, and it 
is known that the conversion of cyclophosphamide to its active form proceeds at least as 
rapidly in the dog as in man (Brock, 1967; Brock & Hohorst, 1963; Mellett, 1966). 
Moreover, there is ample evidence that cyclophosphamide is not a pharmacological 
placebo in the dog, having both toxic (Lee, Castles & Kintner, 1973) and therapeutic effects. 
Leukopaenia (Schmidt et a/., 1964; Lee et al., 1973; Moldovanu, Friedman & Miller, 1966; 
Pallotta, Rail & Ward, 1960; Storb et aI., 1969), which was also documented in the 
present report, anaemia (Lee et al., 1973; Pallotta el al., 1960), haemorrhagic gastroenteritis 
(Epstein et a/., 1969; Lee et ai., 1973) and cystitis (Lee et al., 1973; McClelland, 1963; 
Philips et al., 1961), adrenal insufficiency (Tipton, 1964) and liver function abnormalities 
(Lee et aI., 1973) have all been ascribed in this species to cyclophosphamide administration. 
It has been used successfully in the dog as a diuretic (Zedeck & Mellett, 1964), in the treat-
ment of malignant lymphomas (McClelland, 1963; Moldovanu et a/., 1966) and leukaemias 
(Moldovanu, 1964) and to ablate the bone marrow prior to haematopoietic engraftment 
(Epstein et ai., 1969; Storb et al., 1969). 
Despite its failure-for whatever reasons-as an immunosuppressant in the dog, cyclo-
phosphamide has achieved, although perhaps belatedly, a recognized place in the pharmaco-
logical management of human organ recipients. This fact, in light of the negative results 
obtained in the dog, should caution against rigid adherence to a single test system and 
species in evaluating pharmacological agents of potential clinical applicability. 
Gary O. Zerbe, Ph.D. performed the statistical analyses. 
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